# US 2024/0383852 A1 · Anti-viral compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0383852 A1
- Document ID: US20240383852A1
- Status: Published application
- Kind: A1
- Application number: 18/281,038
- Filed: 2022-03-11
- Published: 2024-11-21
- Earliest claimed: 2021-03-12
- Assignees: INFEX Therapeutics Limited
- Applicants: INFEX Therapeutics Limited
- Inventors: James Kirkham; Ian Cooper; Adam Bunt; Kevin Blades; David Orr; Andrew Wilkinson; Paul Schofield
- Web page: https://patentgrep.com/patent/US20240383852A1

## CPC

- C07D 211/14: with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- A61K 31/36: Compounds containing methylenedioxyphenyl groups, e.g. sesamin
- A61K 31/397: having four-membered rings, e.g. azetidine
- A61K 31/407: condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A61K 31/415: 1,2-Diazoles
- A61K 31/4375: the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A61K 31/4418: having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/451: having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61K 31/4995: Pyrazines or piperazines forming part of bridged ring systems
- A61K 31/505: Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/551: having two nitrogen atoms, e.g. dilazep
- A61P 31/12: Antivirals
- C07D 207/06: with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D 211/08: with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D 211/12: with only hydrogen atoms attached to the ring nitrogen atom
- C07D 213/02: having three double bonds between ring members or between ring members and non-ring members
- C07D 213/38: having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
- C07D 213/56: Amides
- C07D 231/12: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 239/42: One nitrogen atom (nitro radicals C07D239/30)
- C07D 243/08: not condensed with other rings
- C07D 243/14: 1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D 285/08: 1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
- C07D 295/00: Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D 295/033: with the ring nitrogen atoms directly attached to carbocyclic rings
- C07D 317/50: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D 333/20: by nitrogen atoms (nitro, nitroso radicals C07D333/12)
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 401/14: containing three or more hetero rings
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- C07D 407/04: directly linked by a ring-member-to-ring-member bond
- C07D 407/14: containing three or more hetero rings
- C07D 409/12: linked by a chain containing hetero atoms as chain links
- C07D 413/04: directly linked by a ring-member-to-ring-member bond
- C07D 471/18: Bridged systems
- C07D 487/04: Ortho-condensed systems
- C07D 487/10: Spiro-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention relates to compounds that can be used to treat viral infections. The compounds are papain-like protease (PLpro) inhibitors.

## Claims

### Claim 1

A compound of formula (I) or pharmaceutically acceptable salt thereof:
wherein
Y is —C(O)—, —C(S)—, —C(═NR6)—;
-L1- is absent or a linker selected from C1 alkylene, C2-alkenylene, or C2-alkynylene;
X1 is absent or is selected from carbon and nitrogen;
X2, X3 and X5 are each independently selected from carbon, nitrogen, oxygen and sulfur;
X4 is selected from carbon and nitrogen;
wherein when X1 is carbon or nitrogen, X4 is carbon, X2, X3 and X5 are each independently selected from carbon and nitrogen, and no more than two of X1, X2, X3 and X5 may be nitrogen,
wherein when X1 is absent, no more than two of X2, X3, X4 and X5 may be nitrogen and no more than one of X2, X3 and X5 may be oxygen or sulfur;
R1 is selected from the group comprising: C1 or C2 alkyl, C1 or C2 haloalkyl, and C1 or C2 alkylene-R1a; wherein R1a is selected from OR6, SR6, NR6R7, CO2R6 and CONR6R6;
R2 is selected from phenyl, 5- or 6-membered heteroaryl, 5- or 6-membered heterocycloalkyl or C5 or C6 cycloalkyl, and said phenyl, heteroaryl or cycloalkyl is optionally fused to or substituted with a group selected from phenyl, 5- or 6-membered heteroaryl, 5- or 6-membered heterocycloalkyl or C5 or C6 cycloalkyl; wherein any said phenyl or heteroaryl group is optionally substituted with at least one R8 group; or wherein any said heterocycloalkyl or cycloalkyl is optionally substituted with at least one R9 group;
R3, R6 and R11 are each independently at each occurrence selected from the group comprising: H and C1-C6-alkyl;
R4 is independently at each occurrence selected from the group comprising: halo, C1-C6-alkyl, C1-C6-haloalkyl, C1-C6-alkylene-R10, —OR10, cyano, nitro, —NR6R7, —SR10, C(O)R6, C(O)OR6, C(O)NR6R6, —S(O)R10, —S(O)2R10, —S(O)2NR6R6, C3-6 cycloalkyl, C2-6-alkenyl, C2-6-alkynyl, phenyl and 5- or 6-membered heteroaryl;
R5 is selected from the group comprising: —C(O)NR6R14, —C(O)R12, phenyl, 5- or 6-membered heteroaryl; 5-, 6-, 7-, 8-, 9- or 10-membered heterocycloalkyl and cyclopropyl; wherein any said phenyl or heteroaryl group is optionally substituted with at least one R8 group; or wherein any said heterocycloalkyl or cyclopropyl is optionally substituted with at least one R9 group;
wherein when X4 is nitrogen, R5 is selected such that R5 is attached to X4 via a carbon atom;
R7 is independently at each occurrence selected from the group comprising: H, C1-C6-alkyl, C(O)—C1-C6-alkyl and S(O)2—C1-C6-alkyl;
R8 is independently at each occurrence selected from the group comprising: halo, C1-C6-alkyl, C1-C6-haloalkyl, C1-C6-alkylene-R10, —OR10, cyano, nitro, —NR6R7, —SR10, C(O)R10, C(O)OR10, C(O)NR6R10, —S(O)R10, —S(O)2R10, —S(O)2NR6R10, C3-6 cycloalkyl, C2-6-alkenyl, C2-6-alkynyl, 5-, 6-, 7-, 8-, 9- or 10-membered heterocycloalkyl, phenyl and 5- or 6-membered heteroaryl; wherein where R8 is heterocycloalkyl, phenyl or heteroaryl, R8 is optionally substituted where chemically possible with one or more R8c groups;
R8c is independently selected at each occurrence from: halo, C1-C6-alkyl, C1-C6-haloalkyl, C1-C6-alkylene-R10, C1-C6-alkylene-NR6R10, —OR10, C(O)R10, C(O)OR10, C(O)NR6R10;
R9 is independently at each occurrence selected from the group comprising: ═O, ═S, halo, C1-C6-alkyl, C1-C6-haloalkyl, —OR10, cyano, nitro, —NR6R7, —NR11R12, —SR10, C(O)R10, C(O)OR10, C(O)NR6R10, —S(O)R10, —S(O)2R10, —S(O)2NR6R10, C3-6 cycloalkyl, 4-, 5- or 6-membered heterocycloalkyl, C2-6-alkenyl C2-6-alkynyl and C1-C3-alkylene-R9a; wherein R9a is selected from OR6, SR6, S(O)2R6, S(O)2NR6R6, S(O)2Ph, NR6R7, CO2R6, CONR6R6, 4-, 5- or 6-membered heterocycloalkyl, and cyclopropyl;
R10 is independently selected at each occurrence from the group comprising: H, C1-C6-alkyl, C1-C6-haloalkyl, C1-C6-alkylene-R10a, C3-8 cycloalkyl, 4-, 5-, 6-, 7- or 8-membered heterocycloalkyl, phenyl and 5- or 6-membered heteroaryl; wherein R10a is independently selected at each occurrence from C3-8 cycloalkyl, OR6, SR6, S(O)2R6, S(O)2Ph, NR6R7, CO2R6, CONR6R6, phenyl, 5- or 6-membered heteroaryl, and 5- or 6-membered heterocycloalkyl;
R12 is 6-membered heterocycloalkyl; wherein said heterocycloalkyl is optionally substituted with at least one R13 group;
R13 is independently at each occurrence selected from: ═O, ═S, halo, C1-C6-alkyl, C1-C6-haloalkyl, —OR6, cyano, nitro, —NR6R7, —SR6, C(O)R6, C(O)OR6, C(O)NR6R6, —S(O)R6, —S(O)2R6, —S(O)2NR6R6, C3-6 cycloalkyl, C2-6-alkenyl, C2-6-alkynyl and C1-C6-alkylene-R13a; wherein R13a is selected from OR6, SR6, S(O)2R6, S(O)2Ph, NR6R7, CO2R6 and CONR6R6;
R14 is selected from H and C1-C6-alkylene-R14a; wherein R14a is selected from OR6, SR6, S(O)2R6, S(O)2Ph, NR6R7, CO2R6 and CONR6R6; and
n is an integer selected from 0, 1, 2, 3 or 4;
wherein any aforementioned alkyl, alkenyl, alkynyl, haloalkyl, cycloalkyl, heterocycloalkyl, phenyl, heteroaryl, alkylene, alkenylene, alkynylene, C(O)-alkyl and S(O)2-alkyl is optionally substituted, where chemically possible, by 1 to 4 substituents which are each independently selected at each occurrence from the group consisting of: ═O; ═NRa, ═NORa, C1-C4-alkyl, halo, nitro, cyano, C1-C4-haloalkyl, C2-C4-alkenyl, C2-C4-alkynyl, NRaRb, S(O)2Ra, S(O)Ra, S(O)(NRa)Ra, S(O)2NRaRa, CO2Ra, C(O)Ra, CONRaRa, ORa and SRa;
wherein Ra is independently selected from H and C1-C4-alkyl; and Rb is independently selected from H, C1-C4-alkyl, C(O)—C1-C4-alkyl and S(O)2—C1-C4-alkyl.

### Claim 2 (depends on 1)

The compound of claim 1, wherein R5 is 5-, 6- or 7- or 8-membered heterocycloalkyl, wherein said heterocycloalkyl is optionally substituted with at least one R9 group, and wherein said heterocycloalkyl group includes at least two heteroatoms.

### Claim 3 (depends on 1, 2)

The compound of claim 1 or claim 2, wherein R5 is
wherein Z is NR9b, 0 or S(O)q;
x is selected from 0, 1, 2, 3, 4, 5 or 6; and
q is selected from 0, 1 or 2;
R9b is selected from the group comprising: H, C1-C6-alkyl, C1-C6-haloalkyl, C(O)R10, C(O)OR10, C(O)NR6R10, —S(O)R10, —S(O)2R10, —S(O)2NR6R10, C3-6 cycloalkyl, 4-, 5- or 6-membered heterocycloalkyl, C2-6-alkenyl C2-6-alkynyl, C2-C3-alkylene-R9a and CH2-cyclopropyl.

### Claim 4 (depends on 1, 2, 3)

The compound of any of claims 1 to 3, wherein R5 is:
wherein x is selected from 0, 1, 2, 3, 4, 5 or 6; and
R9b is selected from the group comprising: C1-C6-alkyl, C1-C6-haloalkyl, C(O)R6, C(O)OR6, C(O)NR6R6, —S(O)R6, —S(O)2R6, —S(O)2NR6R6, C3-6 cycloalkyl, 4-, 5- or 6-membered heterocycloalkyl, C2-6-alkenyl C2-6-alkynyl, C2-C3-alkylene-R9a and CH2-cyclopropyl.

### Claim 5 (depends on 1)

The compound of claim 1, wherein R5 is selected from the group comprising: —C(O)NR6R14 and —C(O)R12.

### Claim 6

The compound of any preceding claim, wherein X1 is selected from carbon and nitrogen, X4 is carbon, X2, X3 and X5 are each independently selected from carbon and nitrogen, and no more than two of X1, X2, X3 and X5 may be nitrogen.

### Claim 7

The compound of any preceding claim, wherein the ring comprising X1, X2, X3, X4, and X5 is:

### Claim 8

The compound of any preceding claim, wherein the ring comprising X1, X2, X3, X4, and X5 is:
wherein R4 is independently selected from the group comprising: halo, C1-C6-alkyl, C1-C6-haloalkyl, C1-C6-alkylene-R10, —OR10, cyano, nitro, —NR6R7, —SR10, C(O)R6, C(O)OR6, C(O)NR6R6, —S(O)R10, —S(O)2R10, —S(O)2NR6R6, C3-6 cycloalkyl, C2-6-alkenyl, C2-6-alkynyl, phenyl and 5- or 6-membered heteroaryl; and
n1 is an integer selected from 0, 1, 2 or 3.

### Claim 9 (depends on 8)

The compound of claim 8, wherein R4a is C1-4 alkyl.

### Claim 10

The compound of any preceding claim, wherein Y is —C(O)—.

### Claim 11

The compound of any preceding claim, wherein R3 is H.

### Claim 12

The compound of any preceding claim, wherein -L1- is absent.

### Claim 13

The compound of any preceding claim, wherein R1 is C1 or C2 alkyl.

### Claim 14

The compound of any preceding claim, wherein R2 is phenyl, biphenyl, or naphthyl.

### Claim 15 (depends on 1)

The compound of claim 1, wherein the compound is selected from the following compounds or pharmaceutically acceptable salts thereof:

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

A pharmaceutical composition comprising a compound of any of claims 1 to 15, or a pharmaceutically acceptable salt thereof, in association with one or more pharmaceutically acceptable excipients.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The compound of any of claims 1 to 15, or the composition of claim 16, for use in the inhibition of PLpro activity.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

A compound of any of claims 1 to 15, a pharmaceutically acceptable salt thereof, or a composition of claim 16, for use in the treatment of a viral infection.

### Claim 19 (depends on 18)

The compound for use of claim 18, wherein the viral infection is a disease or disorder caused by coronaviruses, rotaviruses, noroviruses, enteroviruses, hepatitis viruses (e.g. HAV, HBV, HCV, HDV, HEV), herpesviruses, papillomaviruses, arboviruses (e.g. West Nile virus, Zika virus, Dengue virus), ebolaviruses, rabies virus, or rubella virus.

### Claim 20 (depends on 19)

The compound or composition for use of claim 19, wherein the disease or disorder is caused by coronaviruses.

### Claim 21 (depends on 20)

The compound or composition for use of claim 20, wherein the disease or disorder is selected from: coronavirus disease 2019 (COVID-19), severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), common cold, or other coronavirus infections.
